BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 18494826)

  • 1. G1 cell cycle regulators in congenital melanocytic nevi. Comparison with acquired nevi and melanomas.
    Stefanaki C; Stefanaki K; Antoniou C; Argyrakos T; Stratigos A; Patereli A; Katsambas A
    J Cutan Pathol; 2008 Sep; 35(9):799-808. PubMed ID: 18494826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell cycle and apoptosis regulators in Spitz nevi: comparison with melanomas and common nevi.
    Stefanaki C; Stefanaki K; Antoniou C; Argyrakos T; Patereli A; Stratigos A; Katsambas A
    J Am Acad Dermatol; 2007 May; 56(5):815-24. PubMed ID: 17437889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin D1 expression in melanocytic lesions of the skin.
    Ramirez JA; Guitart J; Rao MS; Diaz LK
    Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
    Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
    Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship.
    Li Q; Murphy M; Ross J; Sheehan C; Carlson JA
    J Cutan Pathol; 2004 Nov; 31(10):633-42. PubMed ID: 15491322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
    Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
    Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
    Bauer R; Wild PJ; Meyer S; Bataille F; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
    J Clin Pathol; 2006 Jul; 59(7):699-705. PubMed ID: 16565225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A6 protein expression is different in Spitz nevi and melanomas.
    Ribé A; McNutt NS
    Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management.
    Tannous ZS; Mihm MC; Sober AJ; Duncan LM
    J Am Acad Dermatol; 2005 Feb; 52(2):197-203. PubMed ID: 15692463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions.
    Chorny JA; Barr RJ; Kyshtoobayeva A; Jakowatz J; Reed RJ
    Mod Pathol; 2003 Jun; 16(6):525-9. PubMed ID: 12808056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of galanin in melanocytic tumors].
    Gilaberte Y; Vera J; Coscojuela C; Roca MJ; Parrado C; González S
    Actas Dermosifiliogr; 2007; 98(1):24-34. PubMed ID: 17374330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wilms tumor 1 expression present in most melanomas but nearly absent in nevi.
    Perry BN; Cohen C; Govindarajan B; Cotsonis G; Arbiser JL
    Arch Dermatol; 2006 Aug; 142(8):1031-4. PubMed ID: 16924053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large congenital melanocytic nevi and the risk for the development of malignant melanoma. A prospective study.
    Marghoob AA; Schoenbach SP; Kopf AW; Orlow SJ; Nossa R; Bart RS
    Arch Dermatol; 1996 Feb; 132(2):170-5. PubMed ID: 8629825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
    Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
    Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Congenital nevus cell nevi as precursors of melanomas of the skin].
    Schnyder UW; Schneider BV; Maie O; Groh V; Sigg C
    Monatsschr Kinderheilkd; 1987 May; 135(5):259-64. PubMed ID: 3614220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma.
    Flørenes VA; Faye RS; Maelandsmo GM; Nesland JM; Holm R
    Clin Cancer Res; 2000 Sep; 6(9):3614-20. PubMed ID: 10999753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas.
    Gong J; Chen N; Zhou Q; Yang B; Wang Y; Wang X
    J Clin Pathol; 2005 Oct; 58(10):1081-5. PubMed ID: 16189155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of cell cycle and apoptosis regulatory proteins and telomerase in melanocitic lesions.
    Batinac T; Hadzisejdić I; Brumini G; Ruzić A; Vojniković B; Zamolo G
    Coll Antropol; 2007 Jan; 31 Suppl 1():17-22. PubMed ID: 17469743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between melanocytic nevi and malignant melanoma.
    Friedman RJ; Rigel DS; Heilman ER
    Dermatol Clin; 1988 Apr; 6(2):249-56. PubMed ID: 3378371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanocytic nevi and malignant melanoma.
    Metcalf JS; Maize JC
    Dermatol Clin; 1985 Apr; 3(2):217-24. PubMed ID: 3830485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.